Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Jul;61(1):90-5.

Interference of hepatitis B virus surface antigen with natural killer cell function

Interference of hepatitis B virus surface antigen with natural killer cell function

M de Martino et al. Clin Exp Immunol. 1985 Jul.

Abstract

The influence of purified hepatitis B virus surface antigen (HBsAg) preparations or of supernatants derived from PLC/PRF/5 cell line (which produces HBsAg) on human natural killer (NK) activity was examined. Lymphocytes pre-incubated with HBsAg and subsequently washed showed a significant decrease in NK cytotoxicity against K-562 target cells. This effect was reversible and dose-dependent. In addition, pre-incubation with either HBsAg or PLC/PRF/5 supernatants inhibited in a reversible manner lymphocyte--K-562 conjugates and the binding of B73.1 monoclonal antibody (MoAb), which recognizes Fc receptors on NK cells. This effect was not observed with HNK-1, T3, T4, T6, T8 and T11 MoAb. HBsAg was non-toxic to lymphocytes, and ineffective with K-562 target cells. Beta-interferon did not modify HBsAg-mediated inhibition, when added either before or during the contact with HBsAg. Moreover, no modification was observed when neutrophils (at various neutrophil:lymphocyte ratios) were added, even though HBsAg is known to stimulate neutrophils to produce oxygen radicals which may modulate NK activity. We speculate that HBsAg produces these effects by reacting into receptor sites (possibly Fc receptor sites) on NK cell membrane. The overall significance of our results in relation to hepatitis and hepatocellular carcinoma is discussed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1977 Jan 22;1(8004):157-60 - PubMed
    1. J Immunol. 1980 Nov;125(5):2269-76 - PubMed
    1. J Immunol. 1981 Sep;127(3):1024-9 - PubMed
    1. J Clin Invest. 1982 Apr;69(4):876-88 - PubMed
    1. Med Microbiol Immunol. 1982;170(3):155-72 - PubMed

Publication types

LinkOut - more resources